Valvular heart disease poses a rising public health
|
|
- Cory Freeman
- 5 years ago
- Views:
Transcription
1 Transcatheter treatment for valvular heart disease Newer, less invasive techniques provide a wider option for the treatment of severe valvular heart disease in high risk patients. Older patients are likely to benefit from these techniques, as surgical risk increases with age. RY Khamis Specialist Registrar and NIHR Academic Clinical Fellow in Cardiology, Department of Cardiology. Imperial College Healthcare NHS Trust GW Mikhail Consultant Interventional Cardiologist and Honorary Senior Lecturer. Department of Cardiology. Imperial College Healthcare NHS Trust g.mikhail@imperial.ac.uk Valvular heart disease poses a rising public health concern. 1 Evidence suggests that the incidence of valvular heart disease increases significantly with age. 2 A recent study 3 showed that the prevalence of valve disease in the US, corrected for age and sex is 2 5%. Prevalence increased with age, from 0 7% in year olds to 13 3% in the 75 years and older group. As the population in the Western world becomes older, the problem of valvular heart disease will widen, with significant implications to public health. Aortic stenosis is the most common valvular disease in countries where rheumatic fever has a low incidence. 4 The treatment options for severe aortic stenosis, have until recently been limited to aortic valve replacement (AVR), with a few new emerging medical therapy options. 5 Aortic stenosis has a very poor prognosis. 6 Medical therapy on its own offers limited results. Aortic valve replacement, when deemed possible, offers the optimal result. 7 Unfortunately, not all patients are suitable for AVR, mainly due to the rising risk of surgery with worsening comorbidities, and the reluctance by some patients to undertake the risk of major surgery. With the increasing risk of surgery with age, as well as the other factors, such as poor left ventricular function, up to one third of patients treated for valvular heart disease are not referred for surgery. 8 This has created a desperate need for less invasive procedures that offer a reduced operative mortality in the patient populations where the risk of traditional surgery, outweighs the benefits. Transcatheter Aortic Valve Implantation (TAVI) The most important part of undertaking an innovative treatment is risk stratification. 9 In order to reach a conclusion that a patient has either low, moderate or high risk for undergoing major cardiac surgery, a risk stratification model needs to be used. The most commonly used risk stratification model is the EuroScore. 9,10 This is used to predict risk for coronary artery bypass grafting (CABG) patients, and is also in valve surgery, 11, 12 Another risk scoring system is the Society of Thoracic Surgery (STS) scoring system, which has recently been compared to the Euroscore in predicting risk in isolated aortic valve surgery, 13 and found to be more representative of real risk. More importantly, clinical acuity remains a valid way to predict risk. This is where the importance of a multidisciplinary team in patient selection becomes apparent. The British Cardiovascular Intervention Society (BCIS) and the Society for Cardiothoracic Surgery (SCTS) have issued a position statement on TAVI. 14 Centres undertaking the TAVI procedure are obliged to set up a multidisciplinary team of at least two interventional cardiologists and two cardiothoracic surgeons that undertake patient selection. There has to be adequate facilities on site, such as cardiopulmonary bypass facilities, anaesthetic support, vascular surgery support, an intensive care unit that is accustomed to caring for patients GM2 Midlife and Beyond 2009 September 11
2 Interventions after valve operations, interventional radiology and renal support. The selection of patients is a rigorous procedure, where disease severity, anatomy, vascular access, and comorbidities are all carefully considered prior to offering the procedure to the patient. All TAVI procedures are entered in to a central database for audit purposes, and monitored centrally. All operators have to be well experienced, with adequate training and proctored procedures undertaken. A crucial part of the BCIS/SCTS recommendations is that TAVI should currently be reserved for patients who have been considered for traditional AVR surgery, but risk to benefit ratio of open heart surgery and TAVI, to favour TAVI. The usual high risk patient will have a logistic Euroscore of >20 or an STS score of >10. They have also recommended that in ideal circumstances the involvement in the multidisciplinary team of a general physician with experience in the care of the elderly would be appropriate. NICE has also published guidelines 15 in 2008 assessing the safety and efficacy of the procedure, but not the cost-effectiveness. The guidelines stress the need for good clinical governance, informed consent, patient selection by the multidisciplinary team, and procedure data entry into the national UK Central Cardiac Audit Database. There are currently two main transcatheter valve systems, with some others in development, for the treatment of severe aortic stenosis. 16 The basic principle of the percutaneous aortic valve systems is to provide significant relief from aortic stenosis, providing a valve area of 1 5cm or more. 16 Furthermore, the valve system should not interfere with the workings of the mitral valve, or the patency of the coronary arteries, whilst maintaining a profile that allows for little, if any aortic regurgitation. 16 The Edwards SAPIEN Transcatheter Heart Valve 9 (Figure 1) is a bovine pericardium prosthesis mounted on a balloon-expandable stent that is placed in the sub-coronary position, The valve can be placed either antegradely (ie. via the venous system, transeptally, across the mitral valve, and into the aortic root), retrogradely (ie. via the femoral artery, into the aortic valve), or trans-apically (ie. via a small incision in the apex of the heart). The CoreValve ReValving system 17 is a selfexpanding porcine pericardium valve placed percutaneously. The valve is mounted on a selfexpanding nitinol frame. The first balloon expandable valves were Figure 1. The Edwards SAPIEN valve. Courtesy of Edwards Lifesciences deployed via the antegrade approach, 18 this allowed more flexibility in terms of sheath size, as venous distensibility allowed for bigger sheaths to be used. Unfortunately, the complexity of having to effectively cross from the right heart to the left heart in order to deploy the valve made this approach difficult, and less favourable. 19 Following the progress of the prostheses, and the delivery platforms, the retrograde approach via the femoral artery became more popular. 20 A 22F or 24F sheath is inserted in the femoral artery. The insertion of the femoral sheath can be undertaken by a vascular surgeon with a cut-down procedure, in order to minimise vascular complications. The valve is advanced and then positioned under fluoroscopic guidance, and with the aid of transoesophageal echocardiography. Following balloon dilatation, it is then deployed whilst the right ventricle is paced rapidly in order to reduce cardiac output. This results in a reduction of the blood pressure, in order to minimise valve migration. Vascular closure is then undertaken by the vascular surgeon and the patient cared for on the intensive care unit or high dependency unit. If peripheral vessels are not large enough, torturous or diseased, the transapical approach provides a good alternative. 21 Developing this approach has expanded the options available to those patients with a calcified aorta, or peripheral vascular disease. 9,22 Both transfemoral and transapical 12 September 2009 Midlife and Beyond GM2
3 Case study We present a case of an 82 year old gentleman who underwent coronary artery bypass grafting and permanent pacemaker insertion in He presented with shortness of breath on exertion with New York Heart Association Class 3 grade, and was found on transthoracic echocardiography (TOE) to have severe aortic stenosis, with a peak gradient across the valve of 92 mmhg and a valve area of 0.57cm 2. He had bilateral carotid artery disease, and renal impairment. Following cardiac catheterisation, transoesophageal echocardiography, CT aortogram, lung function tests and carotid dopplers, he was discussed in the TAVI multidisciplinary team meeting, and deemed suitable for the transfemoral TAVI approach. Figure 2. The Edwards SAPIEN valve in position pre inflation, with the ECG indicating the onset of rapid right ventriclular (RV) pacing, in preparation for valve deployment. Note the dark object is the transoesophageal echocardiography probe. Previous CABG thoracotomy wires are also apparent, as well as RA, and RV pacing leads, from previous permanent pacemaker (PPM) insertion. Figure 3. The Edwards SAPIEN aortic valve is in situ, with little aortic regurgitation seen on contrast aortography. He underwent TAVI retrogradely, with the EDWARDS SAPIEN valve (Figures 1 and 2), and was discharged without complications 10 days later. On follow up at 6 months, he reported going back to playing golf, and enjoying being able to climb stairs with little shortness of breath. approaches are performed in the Cardiology Catheter Laboratory under fluoroscopic and TOE guidance. The other European-licensed TAVI system, CoreValve, offers a self expanding valve with the advantage of a smaller delivery sheath sizes of 18F. 17 The advantage of not needing a surgical cut-down is somehow counterbalanced by the increased need for permanent pacemaker implantation, which may possibly be due to the prostheses positioning. 9 The evidence for the use of TAVI in high risk patients is now building. The early registries from 2003 and 2004 ( I-REVIVE, and RECAST) 23 showed high mortality (23% at 30 days) major adverse cardiovascular and cerebrovascular event rate at 26%. The antegrade technique used at the time was complicated by the need of transeptal puncture, the guidewires used in the procedure interfered with the workings of the mitral valve and lead to detrimental GM2 Midlife and Beyond 2009 September 13
4 Figure 4. The Mitraclip device in situ, grasping the middle of both the anterior and posterior mitral valve leaflets, creating a double orifice valve. Courtesy of Evalve. mitral regurgitation. 9 This made the antegrade approach unattractive. The retrograde approach was found to be promising, with some pioneers of the technique reporting a steep learning curve, but an eventual success rate of 96% after the first 25 cases. 24 The 30-day mortality was 12%, in comparison to an expected mortality rate of 28%. 24 The PARTNER study (Placement of aortic transcatheter valves trial) is recruiting patients with severe symptomatic aortic stenosis who are poor surgical candidates in the US and Canada. The primary end point is 1-year mortality, comparing TAVI with optimal medical therapy and balloon aortic valve balloon valvulopalsty (BAV), with a second arm comparing TAVI to AVR, using a noninferiority analysis. The transapical approach is also undergoing analysis in large series. 9 Initial 12 month follow up data on 26 patients from Vancouver 25 recently reported an 85%, 12-month survival with no late valve related complications. Data from 14 September 2009 Midlife and Beyond GM2
5 Interventions the European SOURCE Registry 26 demonstrated a procedural success of 92 9%. The 30-day mortality was nearly 10%, with those having a Euroscore >20 fairing the worst. There are many ongoing registry data being collected, most recently BCIS have launched their online TAVI database, which is collecting data from all UK centres. Mitral regurgitation Mitral regurgitation has been found in population studies to be the most common valvular abnormality. 8 The surgical treatment of mitral regurgitation depends on the aetiology, as well as the anatomy of the valve. In the early 1990 s Alfieri developed an edge to edge leaflet repair operation, with the suturing of the edge of mid anterior valve leaflet to the edge of the posterior mitral valve leaflet.27 This technique offered durable results in only a carefully selected group of patients. 27 In functional regurgitation, the annular dilation provides an important substrate in propagating further regurgitation, and this procedure does not include annuloplasty. The new transcatheter technique (MitraClip, by Evalve, San Francisco, CA), provides a similar procedure, percutaneously (figure 4). 28 Access is gained via the femoral vein, a transeptal puncture is undertaken, and the clip is guided into the left ventricle via the left atrium. The clip is deployed, grasping the anterior and posterior mitral valve leaflets, creating a double orifice valve. TOE guidance is used, and optimisation of the position can be undertaken by unclipping, and re-clipping. More than one clip can be used to obtain an optimal result as confirmed by TOE. The Endovascular Valve Edge-to-Edge REpair Study (EVEREST I) study investigated the echocardiographic outcomes of 96 patients who underwent the MitraClip procedure for mitral regurgitation found that at 24 month follow up the procedure decreased the mitral valve area without significant obstruction. 28 No patients required surgery within this time period. The results were independent of the aetiology of the mitral regurgitation. There are ongoing registry data being collected, and the EVEREST II study has finished recruiting, having randomised patients either to percutaneous MitraClip repair versus standard surgical approach. Long term results are awaited. The MitraClip approach is likely to provide a solution for a cohort of patients where the anatomy is favourable and surgical repair less attractive. The EVEREST II study however, unlike the PARTNER trial for aortic stenosis did recruit patients with normal surgical risk, which would directly challenge the standard surgical approach across the risk groups. Midterm results from both the Everest I and Everest II studies were published in August this year with 3 year follow up patients underwent the procedure, with a 74% acute success rate. Kaplan- Meier freedom from death was 95 9%, 94 0%, and 90 1%, and Kaplan-Meier freedom from surgery was 88 5%, 83 2%, and 76 3% at 1, 2, and 3 years. A total of 50 of 76 (66%) successfully treated patients met the primary efficacy endpoint of freedom from death, mitral valve surgery, or mitral regurgitation grade 2 or above at 12 months. Conclusion Newer, less invasive techniques provide a wider option for the treatment of severe valvular disease in the high risk patients. Older patients are likely to benefit from these techniques, as surgical risk increases with age. Newer and more sophisticated systems are being tirelessly developed and tried, with anticipation of better procedural and clinical outcomes. 30 The most important aspect of undertaking the new percutaneous valve treatment techniques is patient selection within a multidisciplinary team, involving physicians with experience in the care of elderly patients, as well as experienced interventional cardiologists and cardiothoracic surgeons. Conflict of interest: none declared References 1. Supino PG, Borer JS, Yin A. The epidemiology of valvular heart disease: an emerging public health problem. Adv Cardiol 2002; 39: Iung B, Vahanian A. Valvular heart diseases in elderly people. Lancet 2006; 368(9540): Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. 16 September 2009 Midlife and Beyond GM2
6 Lancet 2006; 368(9540): Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111(24): Newby DE, Cowell SJ, Boon NA. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart 2006; 92(6): Lester SJ, Heilbron B, Gin K, et al. The natural history and rate of progression of aortic stenosis. Chest 1998; 113(4): Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009; 373(9667): Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003; 24(13): Zajarias A, Cribier AG. Outcomes and safety of percutaneous aortic valve replacement. J Am Coll Cardiol 2009; 53(20): Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16(1): Roques F, Nashef SA, Michel P. Risk factors for early mortality after valve surgery in Europe in the 1990s: lessons from the EuroSCORE pilot program. J Heart Valve Dis 2001; 10(5): ; discussion Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2003; 24(9): Wendt D, Osswald BR, Kayser K, et al. Society of Thoracic Surgeons score is superior to the EuroSCORE determining mortality in high risk patients undergoing isolated aortic valve replacement. Ann Thorac Surg. 2009; 88(2):468 74; discussion BCIS. TAVI: A position statement of the British Cardiovascular Intervention Society (BCIS) and the Society of Cardiothoracic Surgeons (SCTS) NICE. Transcatheter Aortic Valve Implantation Guideline. IPG266Guidance.pdf.Accessed 09/09/ Kodali S, Schwartz A. Transcatheter valve repair and replacement. Annu Rev Med 2009; 60: Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. Euro Intervention 2008;4(2): Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106(24): Cribier A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 2004; 43(4): Eltchaninoff H, Zajarias A, Tron C, et al. Transcatheter aortic valve implantation: technical aspects, results and indications. Arch Cardiovasc Dis. 2008; 101(2): Himbert D, Descoutures F, Al-Attar N, et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol 2009; 54(4): Walther T, Simon P, Dewey T, et al. Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 2007; 116(11 Suppl): I Eltchaninoff H, Tron C, Bauer F, et al. [Aortic bioprosthesis implanted percutaneously: three year follow up]. Arch Mal Coeur Vaiss. 2007; 100(11): 901, Webb JG, Chandavimol M, Thompson CR, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006; 113(6): Ye J, Cheung A, Lichtenstein SV, et al. Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients. J Thorac Cardiovasc Surg. 2009; 137(1): Thomas M. 30-day results of the SOURCE registry: A European registry of transcatheter aortic valve implantation using the Edwards Sapien valve. Presented at: EuroPCR 2009; Barcelona, Spain 27. Lapenna E, De Bonis M, Sorrentino F, et al. Commissural closure for the treatment of commissural mitral valve prolapse or flail. J Heart Valve Dis 2008; 17(3): Herrmann HC, Kar S, Siegel R, et al. Effect of percutaneous mitral repair with the MitraClip device on mitral valve area and gradient. EuroIntervention. 2009; 4(4): Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) Cohort. J Am Coll Cardiol 2009; 54(8): Webb JG, Altwegg L, Masson JB, et al. A new transcatheter aortic valve and percutaneous valve delivery system. J Am Coll Cardiol 2009; 53(20): GM2 Midlife and Beyond 2009 September 17
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationFirst Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always
ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 2 First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not T D, J P. Citation T D, J P.. First Transfemoral
More informationInterventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504
Transcatheter valve-in-valve e implantation for aortic bioprosthetic valve dysfunction Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Your responsibility This
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationVALVULOPATIE: NUOVE SOLUZIONI.
VALVULOPATIE: NUOVE SOLUZIONI www.fisiokinesiterapia.biz Nkomo, Lancet 2006 ELDERLY POPULATION PROJECTION IN USA 65-84 Years Old 85 and Older 77,2 Millions of people 34,8 4,3 30,5 53,8 6,8 47 14,3 62,9
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationTranscatheter aortic valve implantation for severe aortic stenosis a new paradigm for multidisciplinary intervention: A prospective cohort study
Valvular and Congenital Heart Disease Transcatheter aortic valve implantation for severe aortic stenosis a new paradigm for multidisciplinary intervention: A prospective cohort study Rafal Dworakowski,
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationContemporary trans catheter treatment of severe aortic stenosis
Artykuł poglądowy/review article Kardiologia Polska 2011; 69, 5: 487 492 ISSN 0022 9032 Contemporary trans catheter treatment of severe aortic stenosis Współczesne przezcewnikowe leczenie zaawansowanej
More informationPercutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update
Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationTAVR and Cardiac Surgeons
TAVR and Cardiac Surgeons TAVR and Cardiac Surgeons Ragheb Hasan Consultant and Clinical Lead Cardiothoracic Surgeon Manchester Royal Infirmary, Oxford Road, Manchester UK Aortic Stenosis Is A Growing
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of mitral leaflets, 80 Accucinch Annuloplasty system, for mitral regurgitation, 79, 94 95 Accutrak delivery system, for CoreValve
More informationWhy do we need percutaneous
Review Article Hellenic J Cardiol 2010; 51: 348-355 Trans-Catheter Percutaneous Aortic Valve Implantation for Severe Inoperable Aortic Valve Stenosis: Where Do We Stand? George Latsios, Ulrich Gerckens,
More informationPercutaneous Valve Interventions. Percutaneous Valve Interventions
Percutaneous Valve Interventions Stanton J. Rowe President, Percutaneous Valve Interventions Edwards is Best Positioned to Capitalize on Percutaneous Valve Opportunities #1 global valve replacement and
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationSuccessful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement
Advanced Studies in Medical Sciences, Vol. 2, 2014, no. 1, 37-45 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/asms.2014.31213 Successful Transfemoral Edwards Sapien Aortic Valve Implantation
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More information2 Brigham and Women s Hospital, Boston, MA.
Chapter 6: History of Transcatheter Aortic Valve Replacement (TAVR) Bryan Piccirillo, MD 1 ; Pinak B. Shah, MD, FACC 2 1 Brigham and Women s Heart and Vascular Center 2 Brigham and Women s Hospital, Boston,
More informationLearning experience with transapical aortic valve implantation the initial series from Leipzig
Editorial Learning experience with transapical aortic valve implantation the initial series from Leipzig Jörg Kempfert, Thomas Walther Kerckhoff Clinic Bad Nauheim, Germany Corresponding to: Jörg Kempfert,
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationMasterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach
Masterclass III Advances in cardiac intervention Percutaneous valvular intervention a novel approach Professor Roger Boyle CBE National Director for Heart Disease and Stroke London Medical therapy Medical
More informationTranscatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationMeasuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant
More informationChapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine
Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the
More informationPercutaneous valve procedures: an update
1 7 Percutaneous valve procedures: an update Laurens F. Tops 1 Samir R. Kapadia 2 E. Murat Tuzcu 2 Alec Vahanian 3 Ottavio Alfieri 4 John G. Webb 5 Jeroen J. Bax 1 1 Department of Cardiology, Leiden University
More informationInterventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586
Transcatheter aortic valve implantation for aortic stenosis Interventional procedures guidance Published: 26 July 17 nice.org.uk/guidance/ipg586 Your responsibility This guidance represents the view of
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationResults of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery
Results of Transapical Valves A.P. Kappetein Dept Cardio-thoracic surgery Rotterda am, The Netherlands 2002 FIM 2003 2005 2006 2010 THV THV Cribier-Edwards Edwards Edwards Sapien Sapien XT Bovine pericardium
More informationBioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique
Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Charanjit S. Rihal MD MBA Professor and Chair Division of Cardiovascular Diseases Mayo Clinic DISCLOSURES
More informationTranscatheter aortic valve implantation (TAVI): an example of how to organise a TAVI programme
original article Transcatheter aortic valve implantation (TAVI): an example of how to organise a TAVI programme J M ten Berg R Heijmen As the population ages, aortic valve stenosis becomes more prevalent.
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationMitral regurgitation (MR) is the second most
Current Options for Mitral Annuloplasty and Leaflet Repair The benefits and limitations of today s FDA- and CE Mark approved mitral repair technologies. BY ROBERT SCHUELER, MD, AND JAN-MALTE SINNING, MD,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of percutaneous mitral valve leaflet repair for mitral regurgitation Mitral regurgitation
More informationTranscatheter aortic valve implantation for aortic stenosis
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs when the aortic valve
More informationIPAC date: May of 13
National Institute for Health and Care Excellence IP685/3 Transcatheter aortic valve implantation (transcatheter aortic valve replacement) for aortic stenosis Consultation Comments table IPAC date: May
More informationTAVI EN INSUFICIENCIA AORTICA
TAVI EN INSUFICIENCIA AORTICA Cesar Moris Profesor Cardiología Director Departamento del Corazón Hospital Universitario Central de Asturias Universidad de Oviedo OVIEDO -- ESPAÑA CONFLICTO DE INTERESES
More informationTAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
More informationAortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
More informationTranscatheter Valve-In-Valve Implantation for Failed Balloon-Expandable Transcatheter Aortic Valves
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 5, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2012.03.008 Transcatheter
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationHeart Team For TAVI Who and How?
2 nd TAVI Summit 2012, Seoul Corea Heart Team For TAVI Who and How? Alain Cribier, MD, Charles Nicolle Hospital University of Rouen, France Disclosure Edwards Lifesciences Consultant Training / proctoring
More informationThe Acute and 3-Month Outcomes of Transcatheter Aortic Valve Implantation in Taiwan
Original Article??? Acta Cardiol Sin 2011;27:213 20 Transcatheter Aortic Valve Implantation The Acute and 3-Month Outcomes of Transcatheter Aortic Valve Implantation in Taiwan Ying-Hwa Chen, 1,2 Tsui-Lieh
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationTranscatheter Aortic Valve Implantation Management of risks and complications
Transcatheter Aortic Valve Implantation Management of risks and complications TAVI Summit, Seoul, Korea, Spetember 3rd, 2011 Alain Cribier University of Rouen, France Complications of TAVI Depending on
More informationSuccessful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure
Case Report Page 1 of 5 Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure Murat Celik, Uygar Cagdas Yuksel Correspondence to:
More informationTranscatheter aortic valve implantation and pre-procedural risk assesment
Transcatheter aortic valve implantation and pre-procedural risk assesment Alec Vahanian,FESC, FRCP(Edin.) Bichat Hospital University Paris VII, Paris, France Disclosures Relationship with companies who
More informationREVIEW ARTICLE Transcatheter aortic valve insertion: anaesthetic implications of emerging new technology
British Journal of Anaesthesia 103 (6): 792 9 (2009) doi:10.1093/bja/aep311 REVIEW ARTICLE Transcatheter aortic valve insertion: anaesthetic implications of emerging new technology A. A. Klein 1 *, S.
More informationTRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH
TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH Available systems: Edwards (TA and TF) and Core valve. INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,.
More informationTranscatheter aortic valve replacement in high risk patients with different anaesthetic techniques
Endorsed by proceedings in Intensive Care Cardiovascular Anesthesia ORIGINAL ARTICLE Transcatheter aortic valve replacement in high risk patients with different anaesthetic techniques 273 I. Møller Nielsen,
More informationPercutaneous aortic valve therapy: clinical experience and the role of multi-modality imaging
2 0 Percutaneous aortic valve therapy: clinical experience and the role of multi-modality imaging Laurens F. Tops Victoria Delgado Frank van der Kley Jeroen J. Bax Department of Cardiology, Leiden University
More informationPatient selection for transcatheter aortic valve implantation (TAVI) in South Africa
COMMENTARY Patient selection for transcatheter aortic valve implantation (TAVI) in South Africa Martyn Thomas * and Thomas A. Mabin # * Guys and St Thomas Hospital, London, United Kingdom # Vergelegen
More informationSevere left ventricular dysfunction and valvular heart disease: should we operate?
Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict
More informationCardiac Valve/Structural Therapies
Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,
More informationTAVI complication. Possible aetiology and how to manage
TAVI complication. Possible aetiology and how to manage Dr Sanjeevan Pasupati Waikato Hospital, Hamilton, New Zealand Operators: Dr Sanjeevan Pasupati, Mr Nand Kejriwal, Mr Adam Elgamel Valve Positioning
More informationTranscatheter Aortic Valve Implantation Using CoreValve by Transaortic Approach
Case Report http://dx.doi.org/10.12997/jla.2013.2.2.85 pissn 2287-2892 eissn 2288-2561 JLA Transcatheter Aortic Valve Implantation Using CoreValve by Transaortic Approach Kyeong-Hyeon Chun 1, Young-Guk
More informationTAVI Versus Suturless Valve In Intermediate Risk Patients
TAVI Versus Suturless Valve In Intermediate Risk Patients Walid Abukhudair FRCSc President of Saudi Society for Cardiac Surgeons Head of Cardiac Surgery in KFAFH Background AS is the most frequent cardiac
More informationAortic Stenosis. Information on anatomy, diagnosis and treatment options
Information on anatomy, diagnosis and treatment options Hello, I m John I will never forget the day I walked out of my cardiologist s office with the words aortic stenosis in my head. Like you, I just
More informationEstablishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS
Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa
More informationTRANSAPICAL AORTIC VALVE REPAIR
TRANSAPICAL AORTIC VALVE REPAIR Mauro ROMANO M.D. Department of Cardio-Vascular Surgery Institut Cardiovasculaire Paris Sud Institut Hospitalier Jacques Cartier MASSY FRANCE romano.mauro@orange.fr Treatment
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationTAVR in 2017 What we know? What to expect?
Journal of Geriatric Cardiology (2018) 15: 55 60 2018 JGC All rights reserved; www.jgc301.com Perspective Open Access TAVR in 2017 What we know? What to expect? Panagiota Kourkoveli 1,*, Konstantinos Spargias
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationProf. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation
Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationTreatment of acquired valvular heart disease: percutaneous alternatives
16 Oxenham H, Bloomfield P, Wheatley DJ et al. Twenty year comparison of a Björk- Shiley mechanical heart valve with porcine bioprostheses. Heart 2003;89:715 21. 17 Enriquez-Sarano M, Akins CW, Vahanian
More informationAortic Valve Implantation
Transapical Transcatheter Aortic Valve Implantation Early results reveal successful implantation rates in patients with aortic stenosis. BY JOHN C. ALEXANDER, MD, AND SUBHASIS CHATTERJEE, MD Medical progress
More informationPercutaneous Aortic Valvuloplasty: Long-Term Survival
Percutaneous Aortic Valvuloplasty: Long-Term Survival Angioplasty Summit Seoul April 27, 2007 James R. Margolis MD Carmen Paez MD, Kevin Coy MD, Edward Freeman PhD Miami International Cardiology Consultants
More informationStructural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)
Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR) Kathleen Harper DO FACC FACP 87 Chief, Cardiology Section VA Maine Healthcare Kathleen.Harper@va.gov Prevalence of Aortic Stenosis
More informationSummary Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues
ETMIS 2012 ; Vol. 8 : N 0 8 Summary Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues May 2012 A production of the Institut national d excellence
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationThe surgeon s role in transcatheter aortic valve implantation (TAVI)
COMMENTARY The surgeon s role in transcatheter aortic valve implantation (TAVI) Arnaud Van Linden, Johannes Blumenstein, Thomas Walther and Joerg Kempfert Department of Cardiac Surgery, Kerckhoff Klinik
More informationTranscatheter Aortic Valve Replacement (TAVR)
UW MEDICINE PATIENT EDUCATION Transcatheter Aortic Valve Replacement (TAVR) Treatment for aortic stenosis This handout explains when your doctor may advise TAVR to treat aortic stenosis. It includes the
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationResults of Transfemoral or Transapical Aortic Valve Implantation Following a Uniform Assessment in High-Risk Patients With Aortic Stenosis
Journal of the American College of Cardiology Vol. 54, No. 4, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.04.032
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationChapter. Transcatheter aortic valve implantation: role of multimodality cardiac imaging
Chapter 28 Transcatheter aortic valve implantation: role of multimodality cardiac imaging Victoria Delgado, Arnold CT Ng, Miriam Shanks, Frank van der Kley, Joanne D Schuijf, Nico RL van de Veire, 1 Lucia
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationPolicy Specific Section: March 30, 2012 March 7, 2013
Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationTranscatheter Mitral Valve Replacement How Close Are We?
Transcatheter Mitral Valve Replacement How Close Are We? Gregory Pavlides, MD, PhD, FACC, FESC Professor of Medicine Miscia Chair of Interventional Cardiology Director, Cardiac Catheterization Laboratories,
More informationUnderstanding the guidelines for Interventions in MR. Ali AlMasood
Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe
More informationA COMMISSIONING FRAMEWORK FOR TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR SEVERE SYMPTOMATIC AORTIC STENOSIS
A COMMISSIONING FRAMEWORK FOR TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR SEVERE SYMPTOMATIC AORTIC STENOSIS Dr Su Sethi, Consultant in Public Health Medicine, North West Specialised Commissioning
More informationTAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital
TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital Oxford I have financial relationships to disclose Honoraria
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationTechnique of Transcatheter Aortic Valve Implantation
HOSPITAL CHRONICLES 2012, 7(2): 102 107 TECHNIQUES Technique of Transcatheter Aortic Valve Implantation Konstantinos Kalogeras, MD, Manolis Vavuranakis, MD, PhD, FACC, FESC, FSCAI ABSTRACT First Department
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationBernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium
Medium Term Survival and Functional Status in Patients with Severe Aortic Stenosis Treated by Transcatheter Aortic Valvular Implantation in the PARTNER EU Trial Bernard De Bruyne, MD, PhD Cardiovascular
More information